At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLNO Soleno Therapeutics
Post-Mkt 05-12 18:19:15 EDT
52.93
-0.01
-0.02%
盘后52.93
+0.000.00%
17:42 EDT
High52.97Low52.92Vol1.78M
Open52.96D1 Closing52.94Amplitude0.09%
Mkt Cap2.76BTradable Cap2.38BTotal Shares52.12M
T/O94.01MT/O Rate3.96%Tradable Shares44.87M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Soleno Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-08
Soleno Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Soleno Q1 FY26 net income swings to USD 31.38 million; selling, general and administrative expense rises 72% to USD 50.37 million
Reuters  ·  05-08
Soleno Q1 FY26 net income swings to USD 31.38 million; selling, general and administrative expense rises 72% to USD 50.37 million
Neurocrine Posts Strong Q1 as Key Treatments Drive Growth, Morgan Stanley Says
MT Newswires Live  ·  05-06
Neurocrine Posts Strong Q1 as Key Treatments Drive Growth, Morgan Stanley Says
Neurocrine Biosciences Q1 adjusted EPS beats estimates, sales up 44%
Reuters  ·  05-06
Neurocrine Biosciences Q1 adjusted EPS beats estimates, sales up 44%
Neurocrine Q1 FY26 net income rises to $197.9 million; net product sales climb 44% to $811 million
Reuters  ·  05-06
Neurocrine Q1 FY26 net income rises to $197.9 million; net product sales climb 44% to $811 million
Ema's Chmp: Application for Initial Marketing Authorisation Was Withdrawn for Viokat
THOMSON REUTERS  ·  04-24
Ema's Chmp: Application for Initial Marketing Authorisation Was Withdrawn for Viokat
Soleno Therapeutics call volume above normal and directionally bullish
TIPRANKS  ·  04-17
Soleno Therapeutics call volume above normal and directionally bullish
Soleno Therapeutics Cut to Equal-Weight From Overweight by Wells Fargo
Dow Jones  ·  04-17
Soleno Therapeutics Cut to Equal-Weight From Overweight by Wells Fargo
Soleno Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
TIPRANKS  ·  04-17
Soleno Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN), Viridian Therapeutics (VRDN) and Soleno Therapeutics (SLNO)
TIPRANKS  ·  04-11
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN), Viridian Therapeutics (VRDN) and Soleno Therapeutics (SLNO)
HC Wainwright Downgrades Soleno Therapeutics to Neutral From Buy
MT Newswires Live  ·  04-08
HC Wainwright Downgrades Soleno Therapeutics to Neutral From Buy
This Soleno Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Benzinga_recent_news  ·  04-08
This Soleno Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Soleno Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.
Dow Jones  ·  04-08
Soleno Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.
Soleno Therapeutics, Inc. : H.c. Wainwright Cuts to Neutral From Buy
THOMSON REUTERS  ·  04-08
Soleno Therapeutics, Inc. : H.c. Wainwright Cuts to Neutral From Buy
Soleno Therapeutics downgraded to Neutral from Overweight at Piper Sandler
TIPRANKS  ·  04-07
Soleno Therapeutics downgraded to Neutral from Overweight at Piper Sandler
Soleno Therapeutics Inc : Piper Sandler Cuts to Neutral From Overweight; Cuts Target Price to $53 From $145
THOMSON REUTERS  ·  04-07
Soleno Therapeutics Inc : Piper Sandler Cuts to Neutral From Overweight; Cuts Target Price to $53 From $145
Soleno Therapeutics : Oppenheimer Cuts to Perform From Outperform
THOMSON REUTERS  ·  04-07
Soleno Therapeutics : Oppenheimer Cuts to Perform From Outperform
Soleno Therapeutics Inc : Stifel Cuts to Hold From Buy; Cuts Target Price to $53 From $115
THOMSON REUTERS  ·  04-07
Soleno Therapeutics Inc : Stifel Cuts to Hold From Buy; Cuts Target Price to $53 From $115
BUZZ-HC Wainwright lifts PT on Neurocrine after Soleno deal
Reuters  ·  04-07
BUZZ-HC Wainwright lifts PT on Neurocrine after Soleno deal
BRIEF-Soleno Therapeutics Inc - Withdraws Marketing Authorization Application For Viokat In Europe - SEC Filing
Reuters  ·  04-07
BRIEF-Soleno Therapeutics Inc - Withdraws Marketing Authorization Application For Viokat In Europe - SEC Filing

Introduction

Company Name.
Soleno Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Issue price:
--